HS Pipeline Watch: Zura Bio Launches Global Phase 2 Study of Its Dual IL-17A and BAFF Inhibitor in Adults With HS
Zura Bio Limited is launching TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate-to-severe hidradenitis suppurativa (HS).